Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Purpose. This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. Experimental design. Patients received sunitinib 50 mg/day on...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bang, Yung-Jue, Kang, Yoon-Koo, Kang, Won K., Boku, Narikazu, Chung, Hyun C., Chen, Jen-Shi, Doi, Toshihiko, Sun, Yan, Shen, Lin, Qin, Shukui, Ng, Wai-Tong, Tursi, Jennifer M., Lechuga, Maria J., Lu, Dongrui Ray, Ruiz-Garcia, Ana, Sobrero, Alberto
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2010
Materias:
Phase II Studies
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3171673/
https://ncbi.nlm.nih.gov/pubmed/20461441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9438-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares